Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Vertex Pharmaceuticals (VRTX) Valuation Check After Q4 Beat And Growing Confidence In Povetacicept
Vertex Pharmaceuticals (VRTX) reported a Q4 beat, exceeding earnings and revenue expectations, driven by Alyftrek and Casgevy. The company is transitioning from a cystic fibrosis focus to a multi-disease powerhouse with new treatments like Suzetrigine for pain and Povetacicept for renal diseases. While some analyses suggest a modest undervaluation, others view the stock as significantly discounted based on future cash flow.